Kinder Morgan, Inc.
34.43USD
+0.7100 (+2.11%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on KMI.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 18.1B | 13.6B | 13.5B | 15.2B | 18.4B | 18.7B |
| Q1 | 4.1B | 3.4B | 3.4B | 3.9B | 4.5B | 4.9B |
| Q2 | 5.0B | 3.1B | 3.2B | 3.6B | 4.1B | — |
| Q3 | 4.9B | 3.5B | 3.3B | 3.7B | 4.2B | — |
| Q4 | 4.2B* | 3.6B* | 3.6B* | 4.0B* | 4.5B | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 1.12 | 1.06 | 1.17 | 1.37 | 1.56 | 1.57 |
| Q1 | .290 | .300 | .330 | .320 | .440 | .430 |
| Q2 | .280 | .260 | .260 | .320 | .390 | — |
| Q3 | .250 | .240 | .280 | .280 | .340 | — |
| Q4 | .297* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| .266* |
| .300* |
| .448* |
| .386 |
| — |
Debt level and coverage